Researchers in Perth have identified a genetic fault related to calcium absorption in immune cells as a potential key to diagnosing and treating myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), which affects around 250,000 Australians. The study highlights the role of faulty TRPM3 ion channels in ME/CFS and suggests that low-dose naltrexone may help restore their function. Ongoing work aims to develop a blood test for diagnosis and expand clinical trials for naltrexone as a treatment. Personal accounts, such as that of singer Amanda Canzurlo, underscore the debilitating effects of ME/CFS and the need for better understanding and support for patients.
Loading PerspectiveSplit analysis...
